Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia

Tait D. Shanafelt, John C. Byrd, Betsy LaPlant, Clive S. Zent, Tim Call, Charla Secreto, Michael R. Grever, Thomas S. Lin, Neil E. Kay

Research output: Contribution to journalArticle

10 Scopus citations


Serum levels of pro-[vascular endothelial growth factor (VEGF)] and anti- [thrombospondin-1 (TSP)] angiogenic cytokines were prospectively measured in a phase II trial of chemoimmunotherapy (CIT) for chronic lymphocytic leukaemia (CLL) patients (n = 56). Pretreatment VEGF levels were lower among patients who achieved complete remission (CR) or nodular partial remission (nPR) relative to those with partial remission (PR) or stable/progressive disease (median 122.0 pg/ml vs. 246.8 pg/ml; P = 0.03). VEGF:TSP ratio was lower (anti-angiogenic phenotype) among patients who achieved CR/nPR. The pretreatment VEGF:TSP ratio also correlated with overall survival (P = 0.008). A pro-angiogenic profile appears associated with diminished response and inferior survival in CLL patients receiving CIT.

Original languageEnglish (US)
Pages (from-to)660-664
Number of pages5
JournalBritish journal of haematology
Issue number6
StatePublished - Dec 1 2009



  • Angiogenesis
  • Chronic lymphocytic leukaemia
  • Prognostic factors.
  • Therapy
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Hematology

Cite this